Michael J. Overman

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

Michael J. Overman, Ray McDermott, Joseph L. Leach et al. · The Lancet Oncology · 2017 · 2.8K citations · Full text

Medicine, Genetics, Oncology +14

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong et al. · Journal of Clinical Oncology · 2018 · 2.1K citations · Full text

Life Sciences, Immunology, Oncology +16

Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Al B. Benson, Alan P. Venook, Mahmoud M. Al-Hawary et al. · Journal of the National Comprehensive Cancer Network · 2021 · 1.7K citations

Medicine, Oncology, Pathology +17

Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy

Scott Kopetz, George J. Chang, Michael J. Overman et al. · Journal of Clinical Oncology · 2009 · 1.4K citations · Full text

Medicine, Oncology, Surgery +15

Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Al B. Benson, Alan P. Venook, Mahmoud M. Al-Hawary et al. · Journal of the National Comprehensive Cancer Network · 2022 · 819 citations · Full text

Medicine, Oncology, Surgery +17